Instituto de Salud Pública

What Instituto de Salud Pública does

Instituto de Salud Pública de Chile (ISP) is Chile's national public health regulatory authority, established in 1892 and operating as a government state entity under the Ministerio de Salud de Chile. Headquartered in Ñuñoa, Santiago with 501-1000 employees, ISP functions as the official sanitary registration authority for pharmaceuticals, cosmetics, and medical devices, and operates as Chile's reference laboratory network, pharmacovigilance body, and occupational/environmental health assessor. The institution is led by Director Dra. Catterina Ferreccio.

ISP's service portfolio is organized across five wholly-owned operating divisions: Agencia Nacional de Medicamentos (ANAMED) for drug regulation and bioequivalence certification; Agencia Nacional de Dispositivos Médicos (ANDIM) for medical device oversight; Laboratorios Biomédicos for diagnostic testing, transplant management, and the External Quality Evaluation Program (PEEC); Salud Ocupacional; and Salud Ambiental. Citizen-facing programs include ISP Educa (public health education), Remedios Más Baratos (medication price transparency with CENABAST), and the Sanitary Registration Portal (registrosanitario.ispch.gob.cl), which provides self-service lookup of authorized products.

The business model is government-funded: ISP's revenue derives from public budget allocations from the Ministerio de Salud supplemented by regulatory fees for product registrations, sanitary evaluations, and laboratory services. GTM motion is regulatory-led rather than commercial — direct regulatory evaluation, online self-service portals, and regional outreach (ISP en Terreno) — rather than sales-led capture. Customers span the Chilean public healthcare system (drug safety surveillance, reference testing), pharmaceutical and medical device manufacturers (registration, bioequivalence, compliance), and citizens (medication safety alerts, price comparison). ISP maintains international technical collaborations with the U.S. CDC and Brazil's ANVISA to align Chilean capacity with regional regulatory standards.

Name

Instituto de Salud Pública

Legal name

Instituto de Salud Pública de Chile

Website

https://ispch.cl

Company type

Private

Founded year

1892

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Instituto de Salud Pública de Chile (ISP) is the Chilean national public health regulatory authority, regulating medicines, medical devices, cosmetics, and laboratories while running diagnostic testing, pharmacovigilance, and citizen-facing health programs.

Ownership category

akta.pro rank

Product category

Public Health Regulatory Services

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615), Public Administration (92), Testing Laboratories and Services (541380), Administration of Environmental Quality Programs (9241)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industries

International Standards, Norms & Technical Regulatory Bodies (BPADAAAJ), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Public health regulation
• Pharmaceutical regulation
• Medical device oversight
• Biomedical laboratory services
• Bioequivalence certification

Headquarters

HQ city

Ñuñoa

HQ country

Chile

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Others

Revenue model

1. Government Budget Allocation: Public funding from the Chilean government for regulatory and public health services.
2. Regulatory Fees and Service Charges: Fees collected for pharmaceutical product registration, sanitary registrations, laboratory services, and regulatory evaluations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Instituto de Salud Pública de Chile (ISP) is the national public health regulatory authority, providing sanitary registration of pharmaceutical products, cosmetics, and medical devices; bioequivalence certification for generic medications; national health surveillance and pharmacovigilance; biomedical laboratory diagnostic and reference testing; transplant management coordination; and occupational and environmental health services for Chile. It operates through divisions ANAMED (National Medicines Agency), ANDIM (National Medical Devices Agency), Laboratorios Biomédicos, Salud Ocupacional, and Salud Ambiental under the oversight of Chile's Ministry of Health.

Product overview

Instituto de Salud Pública de Chile (ISP) is Chile's national public health regulatory authority, operating as a unified institution rather than a platform-plus-modules architecture. The organization provides a portfolio of regulatory and public health services through its divisions: ANAMED (National Medicines Agency) for medications and cosmetics regulation, ANDIM (National Medical Devices Agency) for medical device oversight, and the Biomedical Laboratories division for diagnostic and reference testing. Key online services include the Sanitary Registry Portal for searching registered products, the Bioequivalence program for generic drug certification, the PEEC (External Quality Evaluation Program) for laboratory proficiency testing, Health Surveillance systems, and the Remedios Más Baratos price comparison program. The institution also provides citizen information services, training programs, and occupational/environmental health assessments.

Differentiator

Problem solved

Functional benefit

Brands

• ISP Educa: Educational portal of the Instituto de Salud Pública for public health education
• Remedios Más Baratos
• PEEC - Programa de Evaluación Externa de la Calidad

Products and services

• Portal de Registro Sanitario
• Bioequivalencia Program
• Programa de Evaluación Externa de la Calidad (PEEC)
• Vigilancia Sanitaria (Health Surveillance)
• Remedios Más Baratos
• Gestión de Trasplante
• Laboratorios Biomédicos
• Sistemas en Línea
• Capacitación Externa

Quantifiable outcome

• Adverse drug event identification and public warnings issued (intestinal angioedema associated with ARBs reported to healthcare providers)
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core, major and minor.

• Healthcare Providers and Patients in ChilecoreOthers · 10 August 2026ISP informs healthcare providers and patients about adverse drug reactions such as intestinal angioedema associated with losartan and other ARB medications, requiring healthcare system vigilance for proper diagnosis and reporting.
• CDC (Centers for Disease Control and Prevention)majorStrategic or Co-development Partner · 1 August 2026Professionals from CDC's Division of Bacterial Diseases visited ISP for a three-day technical collaboration to work on bacterial disease issues, representing international public health cooperation.
• ANVISA (Agencia Nacional de Vigilancia Sanitaria, Brazil)majorStrategic or Co-development Partner · 1 July 2026ISP's Department of National Medical Devices (ANDIM) conducted a technical internship at ANVISA to strengthen medical device regulation in Chile through international regulatory cooperation.
• MercadoLibreminorOthers · 23 July 2025MercadoLibre sought technical evaluation from ISP to operate its own online pharmacy in Chile, requiring regulatory approval and potential law changes for online-only pharmacy operations.
• CONSTRAMET Industrial ChileminorStrategic or Co-development Partner · 1 July 2025Collaboration agreement for preventive management training and capacity building for union workers, implementing a Formation and Training Program under the partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• DIGEMID (Dirección General de Medicamentos, Insumos y Drogas): Peru's national pharmaceutical authority under the Ministry of Health. It carries out registration, quality control, and pharmacovigilance functions closely paralleling ISP's ANAMED mandate.
• COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios): Mexico's federal health risk regulator overseeing medicines, medical devices, and sanitary products. It is structurally comparable to ISP in mandate, scope, and role within a major Latin American public health system.
• INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos): Colombia's national institute for surveillance of medicines and foods. It performs analogous sanitary registration, post-market surveillance, and lab functions relevant to pharmaceutical and consumer-health regulation.
• ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica): Argentina's national regulatory agency for medicines, food, and medical technology. Comparable to ISP in being a national-level sanitary authority operating laboratory and registration functions.
• ANVISA (Agência Nacional de Vigilância Sanitária): Brazil's national health surveillance and regulatory agency. It is a directly comparable national authority covering medicines, medical devices, cosmetics, and food, and is ISP's most active international counterpart.
• ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria): Ecuador's sanitary regulation and control agency, comparable to ISP in scope across medicines, medical devices, cosmetics, and food safety, though at smaller scale.

Emerging players

• Fiocruz (Fundação Oswaldo Cruz): Brazil's public-health research and biological-products institution. It overlaps with ISP on biomedical laboratory services, vaccine/biological quality oversight, and international public health collaboration, but with a stronger research-and-manufacturing orientation.

Broad incumbents

• TGA (Therapeutic Goods Administration, Australia): Australia's therapeutic goods regulator. Comparable in being a national agency that regulates medicines, medical devices, and related products with similar registration and post-market surveillance responsibilities.
• European Medicines Agency (EMA): The EU's central medicines regulator. Its product-approval, pharmacovigilance, and standards-setting functions closely mirror ISP's ANAMED responsibilities at a regional level.
• U.S. FDA: The U.S. federal drug and medical-device regulator. It performs the same statutory functions as ISP (registration, surveillance, lab testing) at vastly greater scale and is a global benchmark rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ispch
• LinkedInlinkedin.com/company/instituto-de-salud-publica

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto de Salud Pública